ISSN: 1838-7640Theranostics
- Current issue
- Volume 15; 2025
- Volume 14; 2024
- Volume 13; 2023
- Volume 12; 2022
- Volume 11; 2021
- Archive
- Advance articles
- Cover images
- Index & coverage
- Cover suggestion
- Special issues
Nanotheranostics 2025; 9(1): 38-51. Full text PDF PubMed PMC
Nanotheranostics 2025; 9(1): 31-37. Full text PDF PubMed PMC
International Journal of Biological Sciences
International Journal of Medical Sciences
Global reach, higher impact
Theranostics 2020; 10(1):437-461. doi:10.7150/thno.38366 This issue Cite
Review
Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
1. Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
2. Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
Citation:
Velikyan I, Eriksson O. Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. Theranostics 2020; 10(1):437-461. doi:10.7150/thno.38366. https://www.thno.org/v10p0437.htm
Other stylesAbstract
In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such critical aspects as structure-activity-relationship, stability, physiological potency, kidney uptake, and dosimetry are discussed.
Keywords: Exendin-4, insulinoma, GLP-1, diabetes, PET, SPECT
Citation styles
APA
Velikyan, I., Eriksson, O. (2020). Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. Theranostics, 10(1), 437-461. https://doi.org/10.7150/thno.38366.
ACS
Velikyan, I.; Eriksson, O. Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. Theranostics 2020, 10 (1), 437-461. DOI: 10.7150/thno.38366.
NLM
Velikyan I, Eriksson O. Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. Theranostics 2020; 10(1):437-461. doi:10.7150/thno.38366. https://www.thno.org/v10p0437.htm
CSE
Velikyan I, Eriksson O. 2020. Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. Theranostics. 10(1):437-461.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.